[go: up one dir, main page]

BRPI0820112B8 - derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento - Google Patents

derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento

Info

Publication number
BRPI0820112B8
BRPI0820112B8 BRPI0820112A BRPI0820112A BRPI0820112B8 BR PI0820112 B8 BRPI0820112 B8 BR PI0820112B8 BR PI0820112 A BRPI0820112 A BR PI0820112A BR PI0820112 A BRPI0820112 A BR PI0820112A BR PI0820112 B8 BRPI0820112 B8 BR PI0820112B8
Authority
BR
Brazil
Prior art keywords
isoxazole
pyridine derivatives
optionally substituted
7alkyl
preparation
Prior art date
Application number
BRPI0820112A
Other languages
English (en)
Inventor
Thomas Andrew
Buettelmann Bernd
Knust Henner
C Lucas Matthew
Jakob-Roetne Roland
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0820112A2 publication Critical patent/BRPI0820112A2/pt
Publication of BRPI0820112B1 publication Critical patent/BRPI0820112B1/pt
Publication of BRPI0820112B8 publication Critical patent/BRPI0820112B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivados de isoxazol-piridina. a presente invenção refere-se a derivados de isoxazol-piridina de fórmula (i) onde: x é o ou nh; r1 é fenila, piridinila ou pirimidinila, cada uma opcionalmente substituída com 1, 2 ou 3 halo, r2 é h ou ch3 ou cf3; r3, r4, r5 e r6 são cada um independentemente h, c1-7alquila opcionalmente substituída, c1-7alcóxi opcionalmente substituído, cn, halo, no2, s-c1-7alquila, benzilóxi opcionalmente substituído, s(o)-c1-7alquila, -c(o)-ra, -c(o)-nrbrc ou um sal farmaceuticamente aceitável do mesmo. os compostos são ativos em sítio de ligação de receptor gaba a (alfa)5 e úteis para o tratamento de distúrbios cognitivos tal como doença de alzheimer.
BRPI0820112A 2007-12-04 2008-11-26 derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento BRPI0820112B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122240 2007-12-04
PCT/EP2008/066225 WO2009071476A1 (en) 2007-12-04 2008-11-26 Isoxazolo-pyridine derivatives

Publications (3)

Publication Number Publication Date
BRPI0820112A2 BRPI0820112A2 (pt) 2015-05-05
BRPI0820112B1 BRPI0820112B1 (pt) 2019-01-15
BRPI0820112B8 true BRPI0820112B8 (pt) 2021-05-25

Family

ID=40329314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820112A BRPI0820112B8 (pt) 2007-12-04 2008-11-26 derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento

Country Status (33)

Country Link
US (6) US20090143371A1 (pt)
EP (2) EP2227467B1 (pt)
JP (1) JP5301557B2 (pt)
KR (2) KR20120102117A (pt)
CN (1) CN101889010B (pt)
AR (1) AR069523A1 (pt)
AU (1) AU2008333326B2 (pt)
BR (1) BRPI0820112B8 (pt)
CA (1) CA2707648C (pt)
CL (1) CL2008003591A1 (pt)
CO (1) CO6351788A2 (pt)
CR (1) CR11454A (pt)
CY (2) CY1116119T1 (pt)
DK (2) DK2767536T3 (pt)
EC (1) ECSP10010230A (pt)
ES (2) ES2531023T3 (pt)
HR (2) HRP20150348T1 (pt)
HU (1) HUE025545T2 (pt)
IL (1) IL205759A (pt)
MA (1) MA31865B1 (pt)
MX (1) MX2010005717A (pt)
MY (1) MY156747A (pt)
NZ (1) NZ585308A (pt)
PE (2) PE20130242A1 (pt)
PL (2) PL2227467T3 (pt)
PT (2) PT2767536E (pt)
RS (2) RS54355B1 (pt)
RU (1) RU2484091C2 (pt)
SI (2) SI2767536T1 (pt)
TW (1) TWI363624B (pt)
UA (1) UA100132C2 (pt)
WO (1) WO2009071476A1 (pt)
ZA (1) ZA201003631B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120102117A (ko) 2007-12-04 2012-09-17 에프. 호프만-라 로슈 아게 아이속사졸로-피리딘 유도체
EP2690095A1 (en) * 2008-10-21 2014-01-29 Camabay Therapeutics, Inc. Aryl gpr120 receptor agonists and uses thereof
EP3725775A1 (en) 2009-02-17 2020-10-21 Syntrix Biosystems, Inc. Pyridine- and pyrimidinecarboxamides as cxcr2 modulators
US8389550B2 (en) * 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) * 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
JP5460858B2 (ja) * 2009-05-05 2014-04-02 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピラゾール誘導体
BRPI1011729A2 (pt) * 2009-05-05 2016-03-15 Hoffmann La Roche derivados de isoxazol-tiazol como um receptor inverso gaba a agonista para uso no tratamento de distúrbios cognitivos
CA2760166C (en) * 2009-05-05 2017-07-18 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
EP2427457B1 (en) * 2009-05-07 2013-07-17 F.Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as gaba modulators
US20110183980A1 (en) * 2009-09-21 2011-07-28 Conn P Jeffrey O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
CN102844313B (zh) 2010-01-28 2016-10-05 哈佛大学校长及研究员协会 提高蛋白酶体活性的组合物和方法
EP2595985A1 (en) 2010-07-19 2013-05-29 Syngenta Participations AG Isoxazole, isothiazole, furane and thiophene compounds as microbicides
EP2595984A1 (en) 2010-07-19 2013-05-29 Syngenta Participations AG Microbicides
US8779149B2 (en) 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
EP2457569A1 (en) 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
KR20150123967A (ko) * 2010-11-05 2015-11-04 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 활성 약학 화합물의 용도
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
US8785435B2 (en) * 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US8604062B2 (en) * 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PT3141542T (pt) 2011-12-28 2020-06-16 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AU2013283488A1 (en) 2012-06-26 2015-01-15 Saniona Aps A phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN104411699B (zh) 2012-06-26 2017-06-13 萨尼奥纳有限责任公司 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2890077T3 (es) * 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PL3102208T5 (pl) 2014-02-07 2024-10-14 Global Blood Therapeutics, Inc. Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu
JP2017071553A (ja) * 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3551627B1 (en) * 2016-12-08 2022-02-16 F. Hoffmann-La Roche AG New isoxazolyl ether derivatives as gaba a alpha5 pam
AU2018323443B2 (en) * 2017-08-28 2024-09-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel gamma aminobutyric acid type a receptor modulators for mood disorders
WO2019122393A1 (en) * 2017-12-22 2019-06-27 Bayer Aktiengesellschaft Hydroxyisoxazolines and derivatives thereof
BR112020025355A2 (pt) * 2018-06-13 2021-03-09 F. Hoffmann-La Roche Ag Derivados de éter de isoxazolila como gaba a alfa5 pam
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
EP4126858A1 (en) 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
AU2022270411A1 (en) 2021-05-05 2023-11-23 Draig Therapeutics Ltd Heteroaryl compounds useful in the treatment of cognitive disorders
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
CN115286636A (zh) * 2022-10-08 2022-11-04 上海赛默罗生物科技有限公司 烟酰胺晶型及其制备方法和用途
TW202448433A (zh) * 2023-06-05 2024-12-16 大陸商武漢人福創新藥物研發中心有限公司 作為α5-GABAA受體調節劑的雜環化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812225A1 (de) * 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
ES2255294T3 (es) 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
GB0125086D0 (en) 2001-10-18 2001-12-12 Merck Sharp & Dohme Novel compounds
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
GB0221443D0 (en) * 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1745027A4 (en) * 2004-05-14 2009-06-03 Irm Llc COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
EP1802566B1 (en) * 2004-10-01 2008-11-26 F. Hoffmann-Roche AG Hexafluoroisopropanol substituted ether derivatives
EP1899299B1 (en) * 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007039389A1 (en) * 2005-09-19 2007-04-12 F. Hoffmann-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
CA2625301A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
KR101121240B1 (ko) * 2005-12-23 2012-06-12 에프. 호프만-라 로슈 아게 아릴-아이속사졸-4-일-옥사다이아졸 유도체
WO2007074078A2 (en) 2005-12-27 2007-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazole derivatives
US7399769B2 (en) 2005-12-27 2008-07-15 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
AU2007207053B2 (en) 2006-01-17 2012-05-24 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
AU2008333320B2 (en) 2007-12-04 2012-12-20 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
KR20120102117A (ko) * 2007-12-04 2012-09-17 에프. 호프만-라 로슈 아게 아이속사졸로-피리딘 유도체
US20100280019A1 (en) * 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles

Also Published As

Publication number Publication date
DK2767536T3 (en) 2015-10-19
HRP20151250T1 (hr) 2015-12-18
CO6351788A2 (es) 2011-12-20
AU2008333326B2 (en) 2013-05-30
CY1116902T1 (el) 2017-04-05
IL205759A (en) 2014-07-31
ECSP10010230A (es) 2010-07-30
NZ585308A (en) 2012-03-30
PE20130242A1 (es) 2013-03-04
US20090143371A1 (en) 2009-06-04
SI2767536T1 (sl) 2015-12-31
WO2009071476A1 (en) 2009-06-11
IL205759A0 (en) 2010-11-30
KR20100075669A (ko) 2010-07-02
US8518974B2 (en) 2013-08-27
RS54355B1 (sr) 2016-04-28
EP2227467B1 (en) 2014-12-31
PE20091073A1 (es) 2009-07-23
HRP20150348T1 (hr) 2015-05-08
US20130281690A1 (en) 2013-10-24
TWI363624B (en) 2012-05-11
MX2010005717A (es) 2010-06-02
BRPI0820112A2 (pt) 2015-05-05
KR101237576B1 (ko) 2013-03-04
TW200924763A (en) 2009-06-16
CN101889010B (zh) 2012-12-05
DK2227467T3 (en) 2015-01-19
ZA201003631B (en) 2013-10-30
US20130274468A1 (en) 2013-10-17
BRPI0820112B1 (pt) 2019-01-15
ES2550994T3 (es) 2015-11-13
MA31865B1 (fr) 2010-11-01
US8877782B2 (en) 2014-11-04
EP2767536B1 (en) 2015-09-02
EP2227467A1 (en) 2010-09-15
CA2707648C (en) 2014-08-12
CL2008003591A1 (es) 2010-01-04
RS53877B1 (sr) 2015-08-31
AR069523A1 (es) 2010-01-27
JP5301557B2 (ja) 2013-09-25
ES2531023T3 (es) 2015-03-09
CY1116119T1 (el) 2017-02-08
MY156747A (en) 2016-03-31
PT2767536E (pt) 2015-11-17
UA100132C2 (en) 2012-11-26
KR20120102117A (ko) 2012-09-17
EP2767536A1 (en) 2014-08-20
PT2227467E (pt) 2015-03-02
RU2484091C2 (ru) 2013-06-10
HK1149756A1 (en) 2011-10-14
SI2227467T1 (sl) 2015-03-31
US20120184538A1 (en) 2012-07-19
PL2227467T3 (pl) 2015-05-29
US20130274469A1 (en) 2013-10-17
US8877783B2 (en) 2014-11-04
CR11454A (es) 2010-06-28
RU2010123923A (ru) 2012-01-10
US20130274467A1 (en) 2013-10-17
AU2008333326A1 (en) 2009-06-11
CN101889010A (zh) 2010-11-17
CA2707648A1 (en) 2009-06-11
HUE025545T2 (en) 2016-03-29
PL2767536T3 (pl) 2016-01-29
US8846719B2 (en) 2014-09-30
US9073908B2 (en) 2015-07-07
JP2011505401A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0608436A2 (pt) derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
BRPI0519287A2 (pt) derivados de amida
TW200738698A (en) Organic compounds
MX2009014001A (es) Derivados de isoxazol-imidazol.
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BR112015006454A2 (pt) derivados de etinila como moduladores de atividade de receptor de mglur5
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
BRPI0517259A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
WO2007006534A3 (en) Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity
UA114008C2 (xx) Похідні етинілу як модулятори активності рецептора mglur5
BR112014006788A2 (pt) derivados de metanossulfonamida substituídos com arila ou n-heteroarila como ligantes de receptor vaniloide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF